Home › Trial NCT05524584
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
- Trial IDNCT05524584
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorUniversity of California, Irvine
- Enrollment20
- Start date2022-08-31
- ConditionsBreast Cancer · Metastatic Breast Cancer · Hormone Receptor-positive Breast Cancer · HER2-negative Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.